EVERSANA Selected by Tonix Pharmaceuticals to Help Launch Tonmya

Tonix Pharmaceuticals (Tonix) is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.

Tonix is committed to developing and marketing therapeutics to treat pain, neurologic, psychiatric and addiction conditions through its central nervous system portfolio and within other areas of high unmet need, including immunology, infectious disease, and rare disease.

Fibromyalgia is a chronic pain disorder resulting from amplified sensory and pain signaling within the CNS. Fibromyalgia is a syndrome comprised of the symptoms: chronic widespread pain, nonrestorative sleep, fatigue, and brain fog. Approximately 10 million U.S. adults are affected, predominantly women1 women.

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials.

Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for Tonmya for the management of fibromyalgia.

To prepare for the launch of Tonmya, Tonix acquired two marketed Rx drugs: Zembrace and Tosymra. Both are indicated for the acute treatment of migraine.

Tonix recently announced that EVERSANA, a leading provider of commercialization services to the global life sciences industry, has been selected to support the launch strategy and commercial planning of Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in the U.S.

EVERSANA will work with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market (GTM) strategy. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers.

The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.